These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 24483782)

  • 41. Deacetylation of nonhistone proteins by HDACs and the implications in cancer.
    Peng L; Seto E
    Handb Exp Pharmacol; 2011; 206():39-56. PubMed ID: 21879445
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Linking epigenetics to lipid metabolism: focus on histone deacetylases.
    Ferrari A; Fiorino E; Giudici M; Gilardi F; Galmozzi A; Mitro N; Cermenati G; Godio C; Caruso D; De Fabiani E; Crestani M
    Mol Membr Biol; 2012 Nov; 29(7):257-66. PubMed ID: 23095054
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Histone deacetylase inhibitors in cancer therapy.
    Lane AA; Chabner BA
    J Clin Oncol; 2009 Nov; 27(32):5459-68. PubMed ID: 19826124
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting histone deacetylases for the treatment of cancer and inflammatory diseases.
    Huang L
    J Cell Physiol; 2006 Dec; 209(3):611-6. PubMed ID: 17001696
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Posttranslational modifications of histone deacetylases: implications for cardiovascular diseases.
    Eom GH; Kook H
    Pharmacol Ther; 2014 Aug; 143(2):168-80. PubMed ID: 24594235
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Histone deacetylase inhibitors as antidiabetic agents: Advances and opportunities.
    Sonthalia M; Roy BS; Chandrawanshi D; Ganesh GV; Jayasuriya R; Mohandas S; Rajagopal S; Ramkumar KM
    Eur J Pharmacol; 2022 Nov; 935():175328. PubMed ID: 36257383
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Epigenetic regulation in bacterial infections: targeting histone deacetylases.
    Grabiec AM; Potempa J
    Crit Rev Microbiol; 2018 May; 44(3):336-350. PubMed ID: 28971711
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.
    Falkenberg KJ; Johnstone RW
    Nat Rev Drug Discov; 2014 Sep; 13(9):673-91. PubMed ID: 25131830
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interplay between histone deacetylases and autophagy--from cancer therapy to neurodegeneration.
    Trüe O; Matthias P
    Immunol Cell Biol; 2012 Jan; 90(1):78-84. PubMed ID: 22124372
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective.
    Gao Y; Zhang H; Lirussi F; Garrido C; Ye XY; Xie T
    Biochem Pharmacol; 2020 Dec; 182():114224. PubMed ID: 32956642
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Roles of Histone Deacetylases in the Regulation of Ovarian Cancer Metastasis.
    Xu L; Yan X; Wang J; Zhao Y; Liu Q; Fu J; Shi X; Su J
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894746
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Role of histone deacetylase on nonalcoholic fatty liver disease.
    Fu S; Yu M; Tan Y; Liu D
    Expert Rev Gastroenterol Hepatol; 2021 Apr; 15(4):353-361. PubMed ID: 33213187
    [No Abstract]   [Full Text] [Related]  

  • 53. Histone deacetylase 7: a signalling hub controlling development, inflammation, metabolism and disease.
    Wang Y; Abrol R; Mak JYW; Das Gupta K; Ramnath D; Karunakaran D; Fairlie DP; Sweet MJ
    FEBS J; 2023 Jun; 290(11):2805-2832. PubMed ID: 35303381
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Medicinal Chemistry Insights into Novel HDAC Inhibitors: An Updated Patent Review (2012-2016).
    Zhan P; Wang X; Liu X; Suzuki T
    Recent Pat Anticancer Drug Discov; 2017; 12(1):16-34. PubMed ID: 27804867
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multiple roles of class I HDACs in proliferation, differentiation, and development.
    Reichert N; Choukrallah MA; Matthias P
    Cell Mol Life Sci; 2012 Jul; 69(13):2173-87. PubMed ID: 22286122
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Histone deacetylases in kidney development: implications for disease and therapy.
    Chen S; El-Dahr SS
    Pediatr Nephrol; 2013 May; 28(5):689-98. PubMed ID: 22722820
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Metal-dependent Deacetylases: Cancer and Epigenetic Regulators.
    López JE; Sullivan ED; Fierke CA
    ACS Chem Biol; 2016 Mar; 11(3):706-16. PubMed ID: 26907466
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Histone deacetylases as therapeutic targets in hematologic malignancies.
    Melnick A; Licht JD
    Curr Opin Hematol; 2002 Jul; 9(4):322-32. PubMed ID: 12042707
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The mechanism and potential targets of class II HDACs in angiogenesis.
    Hou F; Li D; Yu H; Kong Q
    J Cell Biochem; 2018 Apr; 119(4):2999-3006. PubMed ID: 29091298
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recent advances in HDAC-targeted imaging probes for cancer detection.
    Tang C; Wang X; Jin Y; Wang F
    Biochim Biophys Acta Rev Cancer; 2022 Sep; 1877(5):188788. PubMed ID: 36049581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.